RSS-Feed abonnieren
DOI: 10.1055/s-2002-33204
Niedermolekulare Heparine
Low molecular weight heparinsPublikationsverlauf
eingereicht: 11.6.2002
akzeptiert: 19.6.2002
Publikationsdatum:
06. August 2002 (online)

Heparin ist eine wasserlösliche polyanionische Substanz, die vor allem in Mastzellen, aber auch in basophilen Granulozyten gespeichert wird. Lunge, Leber und Darm sind besonders reichhaltig an Mastzellen und daher an Heparin.
Niedermolekulare Heparine sind ein Produkt des nativen Heparins, das, wie zahlreiche Studien der letzten Jahre gezeigt haben, natives Heparin in vielen Indikationen zumindest gleichwertig ersetzen kann. Durch die unkomplizierte Anwendung hat es auch für die ambulante Betreuung zunehmende Bedeutung erlangt.
Literatur
- 1
Weitz J I.
Low-molecular-weight heparins.
NEJM.
1997;
337
688-698
MissingFormLabel
- 2
Hirsh J, Anand S S, Halperin J L, Fuster V.
Guide
to anticoagulant therapy: Heparin.
Circulation.
2001;
103
2994-3018
MissingFormLabel
- 3
De Swart C A, Nijmeyer B, Roelofs J M, Sixma J J.
Kinetics of
intravenously administered heparin in normal humans.
Blood.
1982;
60
1251-1258
MissingFormLabel
- 4
Glimelius B, Busch C, Hook M.
Binding
of heparin on the surface of cultured human endothelial cells.
Thromb
Res.
1978;
12
773-782
MissingFormLabel
- 5
Mahadoo J, Heibert L, Jaques L B.
Vascular
sequestration of heparin in man.
Thromb Res.
1978;
12
79-90
MissingFormLabel
- 6
Frydman A M, Bara L, Le Roux Y, Woler M, Chauliac F, Samana M M.
The antithrombotic
activity and pharmocokinetics of enoxaparine, a low molecular weight
heparin, in humans given single subcutaneous doses of 20 up to 80 mg.
J Clin
Pharmacol.
1988;
28
609-618
MissingFormLabel
- 7
Bradbrook I D, Magnani H N, Moelker H C. et al .
ORG 10 172: a low
molecular weight heparinoid anticoagulant with a long half-life
in man.
Br J Clin Pharmacol.
1987;
23
667-675
MissingFormLabel
- 8
Bergqvist D, Benoni G, Björgell O, Fredin H, Hedlundh U, Nicolas S, Nilsson P, Nylander G.
Low-molecular-weight
heparin (enoxaparin) as prophylaxis against venous thromboembolism
after total hip replacement.
NEJM.
1996;
335
696-700
MissingFormLabel
- 9
Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D’Angelo A, Beltrametti C, Damiani M, Andrioli G C, Pugliese R, Iorio A, Brambilla G.
Enoxaparin plus compression
stockings compared with compression stockings alone in the prevention
of venous thromboembolism after elective neurosurgery.
NEJM.
1998;
339
80-85
MissingFormLabel
- 10
Geerts W H, Jay R M, Code K I, Chen E, Szalai J P, Saibil E A, Hamilton P A.
A comparison of low-dose heparin
with low-molecular-weight heparin as prophylaxis against venous
thromboembolism after major trauma.
NEJM.
1996;
335
701-707
MissingFormLabel
- 11
Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie A G, Demers C, Kovacs M, Geerts W, Kassis J, Desjardins L, Cusson J, Cruickshank M, Powers P, Brien W, Haley S, Willan A.
A
comparison of low-molecular-weight heparin administered primarily
at home with unfractionated heparin administered in the hospital
for proximal deep-vein thrombosis.
NEJM.
1996;
334
677-681
MissingFormLabel
- 12
Koopman M MW, Prandoni P, Piovella F, Ockelford P A, Brandjes D PM, van der Meer J, Gallus A S, Simonneau G, Chesterman C H, Prins M H, Bossuyt P MM, De
Haes H, van den Belt A GM, Sagnard L, D’Azemar P, Büller H R.
Treatment
of venous thrombosis with intravenous unfractionated heparin administered
in the hospital as compared with subcutaneous low-molecular-weight
heparin administered at home.
NEJM.
1996;
334
682-687
MissingFormLabel
- 13
Breddin H K, Hach-Wunderle V, Nakov R, Kakkar V V.
Effects of
a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism
in patients with deep-vein thrombosis.
NEJM.
2001;
344
626-631
MissingFormLabel
- 14
Simonneau G, Sors H, Charbonnier B, Page Y, Laaban J -P, Azarian R, Laurent M, Hirsch J -L, Ferrari E, Bosson J -L, Mottier D, Beau B.
A comparison of low-molecular-weight
heparin with unfractionated heparin for acute pulmonary embolism.
NEJM.
1997;
337
663-669
MissingFormLabel
- 15
Wallentin L, Ohlsson J, Swahn E.
Low-molecular-weight
heparin during instability in coronary artery disease.
Lancet.
1996;
347
561-568
MissingFormLabel
- 16
Klein W, Buchwald A, Hillis S E, Monrad S, Sanz G, Turpie A GG, van der Meer J, Olaisson E, Undeland S, Ludwig K.
Comparison of low-molecular-weight
heparin with unfractionated heparin acutely and with placebo for
6 weeks in the management of unstable coronary artery disease.
Circulation.
1997;
96
61-68
MissingFormLabel
- 17
Cohen M, Demers C, Gurfinkel E P, Turpie A GG, Fromell G J, Goodman S, Langer A, Califf R M, Fox K AA, Premmereur J, Bigonzi F.
A comparison of low-molecular
weight heparin with unfractionated heparin for unstable coronary
artery disease.
NEJM.
1997;
337
447-452
MissingFormLabel
- 18
Antmann E M, McCabe C H, Gurfinkel E P, Turpie A GG, Bernink P JLM, Salein D, de
Luna A B, Fox K, Lablanche J -M, Radley D, Premmereur J, Braunwald E.
Enoxaparin
prevents death and cardiac ischemic events in unstable angina/non-Q-wave
myocardial infarction. Results of the thrombolysis in myocardial
infarction (TIMI) 11B trial.
Circulation.
1999;
100
1593-1601
MissingFormLabel
- 19
Yusuf S. for the Direct Thrombin Inhibitor Trialists’ Collaborative
Group .
Direct thrombin inhibitors in acute coronary
syndromes: principal results of a meta-analysis based on individual patients’ data.
Lancet.
2002;
359
294-302
MissingFormLabel
- 20
Montalescot G, Polle V, Collet J P, Leprince P, Bellanger A, Gandjbakhch I, Thomas D.
Low
molecular weight heparin after mechanical heart valve replacement.
Circulation.
2000;
101
1083-1086
MissingFormLabel
- 21
Kay R, Wong K S, Vu Y L, Chan Y W, Tsoi T H, Ahuja A T, Chan F L, Fong K Y, Law C B, Wong A, Woo J.
Low-molecular-weight heparin
for the treatment of acute ischemic stroke.
NEJM.
1995;
333
1588-1593
MissingFormLabel
- 22
Brott T, Bogousslavsky J.
Treatment of acute
ischemic stroke.
NEJM.
2000;
343
710-722
MissingFormLabel
- 23
Dimitrakakis C, Papageorgiou P, Papageorgiou I, Antzaklis A, Sakarelou N, Michalas S.
Absence of transplacental
passage of the low molecular weight heparin enoxaparin.
Haemostasis.
2000;
30
243-248
MissingFormLabel
- 24
Sanson B J, Lensing A W, Prins M H, Ginsberg J S, Barkagan Z S, Lavenne-Pardonge E, Brenner B, Dulitzky M, Nielsen J D, Boda Z, Turi S, Mac-Gillavry M R, Hamulyak K, Theunissen I M, Hunt B J, Buller H R.
Safety of low-molecular-weight
heparin in pregnancy: a systematic review.
hromb Haemost.
1999;
81
668-672
MissingFormLabel
- 25
Malsch R, Harenberg J, Guerrini M, Torri G, Casu B, Heene D L.
Semisynthesis and
analysis of lipophilically modified unfractionated and low molecular
mass heparins.
Semin Thromb Hemost.
1994;
20
182-192
MissingFormLabel
- 26
Warkentin T E, Levine M N, Hirsh J, Horsewood P, Roberts R S, Gent M, Kelton J G.
Heparin-induced thrombocytopenia
in patients treated with low-molecular-weight heparin or unfractionated
heparin.
N Engl J Med.
1995;
332
1330-1335
MissingFormLabel
- 27
Muir J M, Hirsh J, Weitz J I, Andrew M, Young E, Shaughnessy S G.
A histomorphometric
comparison of the effects of heparin and low-molecular-weight heparin
on cancellous bone in rats.
Blood.
1997;
89
3236-3242
MissingFormLabel
- 28
Bhandari M, Hirsh J, Weitz J I, Young E, Venner T J, Shaughnessy S G.
The effects
of standard and low molecular weight heparin on bone nodule formation
in vitro.
Thromb Haemost.
1998;
80
413-417
MissingFormLabel
- 29
Smith B S, Gandhi P J.
Pharmacokinetics
and phamacodynamics of low-molecular-weight heparins and glycoprotein
IIb/IIIa receptor antagonists in renal failure.
J
Thrombosis Thrombolysis.
2001;
11
39-48
MissingFormLabel
- 30
Turpie A GG, Gallus A S, Hoek J A.
A synthetic pentasaccharide for the prevention
of deep-vein thrombosis after total hip replacement.
NEJM.
2001;
344
619-625
MissingFormLabel
- 31
Eriksson B I, Bauer K A, Lassen M R, Turpie A GG.
Fondaparinux
compared with enoxaparin for the prevention of venous thromboembolism
after hip-fracture surgery.
NEJM.
2001;
345
1298-1304
MissingFormLabel
- 32
Bauer K A, Eriksson B I, Lassen M R, Turpie A GG.
Fondaparinux
compared with enoxaparin for the prevention of venous thromboembolism
after elective major knee surgery.
NEJM.
2001;
345
1305-1310
MissingFormLabel
Autoren
Dr. F. Schröder,
Dr. T. Weiss
Abteilung
für Kardiologie und Angiologie, Medizinischen Hochschule
Hannover
Carl-Neuberg-Straße 1
30625 Hannover